CSL (ASX:CSL) has put kidney and liver disease firmly in focus, committing an upfront US$355 million to partner with Alentis ...

Market capitalization was AUD 88.4 billion, while 579,614 shares traded against a 1,281,785 average.

The shares have recovered sharply, so I wanted to see whether the valuation still stacks up. The post CSL shares: Buy, hold, ...

CSL (ASX:CSL) remains a core Bluechip Stocks name through its global plasma therapeutics and vaccine operations.

Haemonetics (NYSE:HAE) shares jumped over 13% to $115.20 on Thursday after CSL set out a timetable for moving its US plasma collection centers onto the company's devices. CSL Limited (ASX:CSL), the ...

CSL signed an exclusive global deal with Alentis for lixudebart, targeting rare kidney and liver disease. What it means for the group.

The best shares don't always make the best investments. The post I compared 5 of the ASX's best shares. Here's which one I'd ...

CSL ( ) has provided an announcement. CSL Limited is a global biotechnology company that develops and supplies vaccines, plasma-derived therapies, and specialty biopharmaceuticals ...

After the disaster at bellwether stock CSL, the overseas misadventures of Ramsay and even a downgrade this year for sector stalwart Cochlear, it seemed healthcare stocks were consigned to the dustbin.